→
Johnson & Johnson's financial metrics present a mixed outlook influenced by legal settlements and growth rates.
Johnson & Johnson has a market capitalization of $660.51B and is currently priced at $271.88, reflecting a change of +1.58% for the day. The P/E ratio stands at 24.65, with a P/S ratio of 7.01 and a P/B of 8.10. Year-over-year EPS growth is reported at 90.50%, while revenue growth is at 6.05%. The company has a D/E ratio of 0.48 and a current ratio of 1.03.
Some investors cite Johnson & Johnson's impressive EPS growth of 90.50% year-over-year, indicating strong profitability. Additionally, the company's revenue growth of 6.05% year-over-year suggests a solid demand for its pharmaceutical products.
Conversely, concerns about ongoing legal challenges, including a proposed $5.5B settlement for talc litigation, may impact investor sentiment and financial stability. The company's relatively high P/E ratio of 24.65 could also raise questions about valuation.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start. Pro unlocks the full terminal at $20/mo.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Johnson & Johnson has a market capitalization of $660.51B and is currently priced at $271.88, reflecting a change of +1.58% for the day. The P/E ratio stands at 24.65, with a P/S ratio of 7.01 and a P/B of 8.10. Year-over-year EPS growth is reported at 90.50%, while revenue growth is at 6.05%. The company has a D/E ratio of 0.48 and a current ratio of 1.03.
Conversely, concerns about ongoing legal challenges, including a proposed $5.5B settlement for talc litigation, may impact investor sentiment and financial stability. The company's relatively high P/E ratio of 24.65 could also raise questions about valuation.
Some investors cite Johnson & Johnson's impressive EPS growth of 90.50% year-over-year, indicating strong profitability. Additionally, the company's revenue growth of 6.05% year-over-year suggests a solid demand for its pharmaceutical products.
Some investors cite Johnson & Johnson's impressive EPS growth of 90.50% year-over-year, indicating strong profitability. Additionally, the company's revenue growth of 6.05% year-over-year suggests a solid demand for its pharmaceutical products. Conversely, concerns about ongoing legal challenges, including a proposed $5.5B settlement for talc litigation, may impact investor sentiment and financial stability. The company's relatively high P/E ratio of 24.65 could also raise questions about valuation.
Johnson & Johnson has a market capitalization of $660.51B and is currently priced at $271.88, reflecting a change of +1.58% for the day. The P/E ratio stands at 24.65, with a P/S ratio of 7.01 and a P/B of 8.10. Year-over-year EPS growth is reported at 90.50%, while revenue growth is at 6.05%. The company has a D/E ratio of 0.48 and a current ratio of 1.03.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for JNJ at helmterminal.dev/analyze/JNJ, updated continuously during US market hours. No signup required.